Survey: Access to Treatments for the Management of Immune-Related Colitis

Last year an Immunotherapy Specialist Interest Group was established at BOPA, and we are delighted to invite you to take part in our first piece of work.

As a group, we are keen to address the known disparity across the UK with regards to access to drugs for immune-related adverse effects.

To begin with, we aim to gain further perspective of access to vedolizumab for immune-related colitis for which your involvement is vital. Please find below the link to take you to the survey, which should take between 5-10 minutes to complete. Analysis of these results will be used to drive some real-world data collection, therefore please do share your email address if you are keen to collaborate.

https://forms.office.com/Pages/ResponsePage.aspx?id=slTDN7CF9UeyIge0jXdO4_Ov3JPaZfRCoHg-BdRtaARURFdHWDBaUVIxUzJWTTdVSVdXVDVaVFE1SS4u

Please get in touch if you have any queries and thank you for your contribution.

Alice, Meera, Faye, Jo and Kavita

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article